Trial Profile
A retrospective study of cabazitaxel and abiraterone acetate in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel: CAST
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Sep 2015
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Abiraterone acetate
- Indications Prostate cancer
- Focus Therapeutic Use
- 23 Sep 2015 New trial record
- 15 Mar 2015 Primary endpoint (Overall survival), has been not met, as per an article published in the International Journal of Cancer.